金沙官网平台

金沙官网9304

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.金沙官网平台



金沙官网9304

The safety of our patients is very important to us. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

By reporting any side effects that you may experience, you are helping to provide 更多 资讯rmation on the safety of our medicines. Report a possible side-effect to AstraZeneca by 'report side-effect' below. If you are based in the UK, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.



Cardiovascular, Renal and Metabolic Diseases金沙官网平台

Please note that the 产品介绍s mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific 资讯rmation is available from your local AstraZeneca company.

 

Atacand, Atacand HCT, Atacand Plus金沙官网平台

candesartan cilexetil

Brilinta/Brilique金沙官网平台

ticagrelor

Bydureon金沙官网平台

exenatide

Byetta金沙官网平台

exenatide injection

Crestor金沙官网平台

rosuvastatin

Farxiga/Forxiga金沙官网平台

dapagliflozin

Komboglyze金沙官网平台

saxagliptin and metformin HCl

Kombiglyze XR金沙官网平台

saxagliptin and metformin XR

Lokelma金沙官网平台

Sodium zirconium cyclosilicate

Onglyza金沙官网平台

saxagliptin

Plendil, Modip, Splendil, Munobal, Flodil 金沙官网平台

felodipine

Qtern金沙官网平台

dapagliflozin and saxagliptin

Seloken ZOK, Toprol-XL, Betaloc ZOK金沙官网平台

metoprolol succinate

Symlin金沙官网平台

pramlintide acetate

Tenormin, Tenormine, Prenormine, Atenol 金沙官网平台

atenolol

XIGDUO金沙官网平台

dapagliflozin and metformin HCI

XIGDUO XR 金沙官网平台

dapagliflozin and metformin HCI extended-release

Zestril金沙官网平台

lisinopril dihydrate

Oncology金沙官网平台

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

 

Arimidex 金沙官网平台

anastrozole

Calquence金沙官网平台

acalabrutinib

Casodex, Cosudex金沙官网平台

bicalutamide

Enhertu金沙官网平台

trastuzumab deruxtecan

Faslodex 金沙官网平台

fulvestrant

Imfinzi金沙官网平台

durvalumab

Iressa金沙官网平台

gefitinib

Lynparza金沙官网平台

olaparib

Tagrisso金沙官网平台

osimertinib

Zoladex金沙官网平台

goserelin acetate implant

Infection and Vaccines金沙官网平台

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

 

Synagis 金沙官网平台

palivizumab

Fluenz Tetra/FluMist Quadrivalent金沙官网平台

influenza vaccine live, intra-nasal

Neuroscience金沙官网平台

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

 

Diprivan金沙官网平台

propofol

EMLA金沙官网平台

EMLA

Movantik/Moventig 金沙官网平台

naloxegol

Naropin金沙官网平台

ropivacaine

Seroquel IR金沙官网平台

quetiapine fumarate

Seroquel XR金沙官网平台

quetiapine fumarate

Xylocaine金沙官网平台

lidocaine

Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon 金沙官网平台

zolmitriptan

Respiratory金沙官网平台

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

 

Accolate, Accoleit, Vanticon金沙官网平台

zafirlukast

Bevespi Aerosphere金沙官网平台

glycopyrronium/formoterol fumarate

Breztri Aerosphere金沙官网平台

budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules金沙官网平台

terbutaline

Bricanyl Turbuhaler金沙官网平台

terbutaline in a dry powder inhaler

Daliresp/Daxas金沙官网平台

roflumilast

Duaklir Genuair金沙官网平台

aclidinium/formoterol

Eklira Genuair/Tudorza/Bretaris金沙官网平台

aclidinium, a LAMA

Fasenra金沙官网平台

benralizumab

Oxis Turbuhaler金沙官网平台

Oxis Turbuhaler

Pulmicort Respules金沙官网平台

budesonide inhalation suspension

Pulmicort Turbuhaler金沙官网平台

budesonide

Rhinocort金沙官网平台

budesonide

Symbicort pMDI金沙官网平台

budesonide/formoterol

Symbicort Turbuhaler金沙官网平台

budesonide/formoterol

Gastrointestinal金沙官网平台

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

 

Losec, Gastroloc, Mopral, Omepral, Prilosec金沙官网平台

omeprazole

Nexium金沙官网平台

esomeprazole

Vimovo金沙官网平台

naproxen and esomeprazole magnesium


金沙官网9304

We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.

 


Veeva ID: Z4-17492    

Date of next review: 07/06/2021